RxSight (RXST) Set to Announce Quarterly Earnings on Thursday

RxSight (NASDAQ:RXST) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect RxSight to post earnings of $0.02 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. The business had revenue of $34.89 million during the quarter, compared to analysts’ expectations of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm’s quarterly revenue was up 67.6% compared to the same quarter last year. During the same period last year, the company posted ($0.40) earnings per share. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RxSight Stock Performance

RXST stock opened at $51.21 on Thursday. The stock has a market cap of $1.89 billion, a P/E ratio of -50.21 and a beta of 1.20. The firm has a 50 day simple moving average of $51.83 and a 200 day simple moving average of $53.63. RxSight has a 52 week low of $21.14 and a 52 week high of $66.54.

Insider Activity

In other news, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $50.64, for a total value of $156,984.00. Following the transaction, the insider now owns 42,246 shares of the company’s stock, valued at $2,139,337.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 49,310 shares of company stock valued at $2,370,917 over the last 90 days. 9.36% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on the stock. BTIG Research raised their price target on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday. They issued a “buy” rating and a $72.00 target price for the company. Oppenheimer reduced their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Company reduced their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Stifel Nicolaus reduced their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.